Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angiopathy24.03.02.007--Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000362%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Appetite disorder19.09.01.002; 14.03.01.0040.001664%Not Available
Bladder disorder20.03.01.0020.000241%Not Available
Cardiac disorder02.11.01.0030.002942%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.002652%Not Available
Infarction24.04.02.0170.000362%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.0890.001905%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Oesophageal disorder07.11.02.0010.000940%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.075396%
Ill-defined disorder08.01.03.0490.003207%Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.0130.030549%Not Available
Obstructive airways disorder22.03.01.0110.000241%Not Available
Hepatic lesion09.01.08.0050.000241%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Lung neoplasm22.08.01.006; 16.19.04.0010.000964%Not Available
Pigmentation disorder23.05.03.0010.000241%Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.006--
Increased upper airway secretion22.12.03.0070.000482%Not Available
Bowel movement irregularity07.02.03.003--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.002194%Not Available
Lichenoid keratosis23.01.01.0040.000530%Not Available
The 10th Page    First    Pre   10 11 12    Next   Last    Total 12 Pages